在患有MASLD的患者中,与肝纤维化严重程度相关的血小板血栓 B2的过度产生
Francesco Baratta1, Nicholas Cocomello2, Guido Carpino3
1Geriatric Unit, Department of Internal Medicine and Medical Specialties, AOU Policlinico Umberto I, Rome, Italy.
Thrombosis research
|November 22, 2025
概括
血小板环氧化酶-1 (COX-1) 的激活,通过增加的血红素B2 (TxB2) 水平来表明,随着代谢功能障碍相关的脂肪酸性肝病 (MASLD) 的严重程度而恶化. 这种血小板激活与MASLD患者的肝纤维化进展有关.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 心血管生物学 心血管生物学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 血小板环氧化酶-1 (COX-1) 激活与代谢功能障碍相关的稳定性肝病 (MASLD) 病原发生有关.
- 对于COX-1激活和MASLD严重程度之间的确切关系尚不清楚.
- 在MASLD患者中研究血小板COX-1激活对于了解疾病进展至关重要.
研究的目的:
- 在被诊断为MASLD的患者中调查血小板COX-1激活.
- 评估血小板激活标志物与MASLD严重程度之间的相关性.
- 探索MASLD中血小板激活和肝纤维化之间的关联.
主要方法:
- 与活检证明的MASLD患者进行横截面研究设计.
- 测量血清血红素B2 (TxB2) 作为生物标志物,用于体外COX-1激活潜力.
- 对体内血小板激活和氧化应激生物标志物 (sNOX2-dp,HBA) 的血sP-选择素的评估.
主要成果:
- 血清TxB2水平逐渐从简单肥胖症 (MASLD-SS) 增加到肥胖肝炎 (MASH) 和肝硬化.
- 血清TxB2和sNOX2-dp水平与纤维化阶段正相关,与HBA相反.
- 多变量分析证实了TxB2与肝纤维化阶段和sNOX2-dp的关联.
结论:
- 血小板TxB2的过度产生随着MASLD的严重程度而增加,从MASLD-SS到MASH和肝硬化.
- 升高的TxB2与MASLD中的肝纤维化程度显著相关.
- 这些发现支持了血小板COX-1激活在MASLD病变发生过程中的作用.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K
Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K


